Protein mono-ADP-ribosyltransferase PARP3

BE0004049ProteinHumansPARP3

Mono-ADP-ribosyltransferase that mediates mono-ADP-ribosylation of target proteins and plays a key role in the response to DNA damage (PubMed:16924674, PubMed:19354255, PubMed:20064938, PubMed:21211721, PubMed:21270334, PubMed:23742272, PubMed:24598253, PubMed:25043379, PubMed:28447610). It is acted on by 5 drugs in DrugBank.

Gene name
PARP3
UniProtKB entry
Q9Y6F1Swiss-Prot
Cellular location
Nucleus
Residues / weight
533 residues · 60,089 Da
Also known as
2.4.2.- · ADP-ribosyltransferase diphtheria toxin-like 3 · ADPRT-3 · ADPRT3 · ADPRTL3

Resolves to

Protein
UniProtQ9Y6F1UniProt namePARP3_HUMAN
Gene
HGNCHGNC:273NCBI Gene10039GenBank29788060GeneCardsPARP3
Pharmacology
IUPHAR/GtoPdb2864KEGGhsa:10039
Structure
PDB2EOCPDB3C49PDB3C4H
Drugs

What you can answer from here — as of September 03, 2024

5DrugsApproved to experimental, with action, bond type and pharmacological action
Sign in
1Clinical trialTrials of drugs acting on it, by phase and status
Sign in
10GO termsFunction, process and component, as structured annotations
Sign in
3Pfam domainsDomain architecture mapped to Pfam families and clans
Sign in
28+ReferencesStructured and connected to the statements they support
Sign in

Which approved drugs act on Protein mono-ADP-ribosyltransferase PARP3, how selective are they, and which programs against it are still in active trials?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In